

GluSense Glyde™ CGM – A Long-term Implantable Glucose Sensor

Boaz Brill
CEO

- **Investment Rational**
GluSense is developing Glyde™, a continuous glucose sensor for diabetes patients, comprising a miniature sensor, injected under the skin for a duration of a full year, a wearable device for implant powering and signal detection, and a mobile application for user interface and data upload to cloud. Management strengths include a proven track record in the development of challenging multi-disciplinary products and experience in medical devices.
- **Business Strategy**
GluSense is currently addressing both US and the European market and is planning on starting a first in human study in 2019. Revenues are expected to start in 2022.
- **Core Technology**
Glucose measurement is based on the optical measurement of an optimized glucose-sensitive fluorescent biosensor. GluSense unique technology is the use of genetically modified live cells in order to continuously replenish the biosensor in-situ, allowing the implant, by design, to function with no lifetime limitation. The core technology, including means to protect the cells while implanted in animal, have been extensively tested in multiple animal studies.
- **Product Profile/Pipeline**
Currently, a fully-functional first generation product is under large animal studies and good glucose response was demonstrated. In previous studies, using an early prototype, implant functionality was demonstrated for up to 9 months. Apart from being a stand-alone glucose sensor, Glyde could fit into an “artificial pancreas” system via a collaboration with an existing insulin-pump vendor. An artificial pancreas will eliminate patients’ hassle in managing their condition 24/7, while improving their long-term health and quality of life.
- **What's Next?**
Preclinical testing are on-going and planned to be completed by end of 2018. First in Human clinical study is planned to start in Q1/2019 in Slovenia with a leading KOL.